Related Experiment Video
Updated: Jun 4, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Efficacy and tolerability of multidrug therapy for hypertriglyceridemia
Venkateshwar R Polsani1, Vijay Nambi, Salim S Virani
1Section of Atherosclerosis and Vascular Medicine, Department of Medicine, Baylor College of Medicine, 6565 Fannin, M.S. A-601, Houston, TX 77030, USA; and Center for Cardiovascular Disease Prevention, Methodist DeBakey Heart and Vascular Center, Houston, TX.
Journal of Clinical Lipidology
|February 5, 2011
Summary
Multidrug therapy (≥3 agents) effectively manages severe hypertriglyceridemia, significantly reducing lipid levels over two years. This combination approach proved safe and well-tolerated in patients with high triglycerides.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Disorders
Background:
- Limited data exists on the efficacy and safety of using more than two drugs for hypertriglyceridemia treatment.
- Existing evidence supports single-drug and some two-drug combinations for managing high triglyceride levels.
Purpose of the Study:
- To evaluate the efficacy and safety of using multiple medications (three or more agents) for managing hypertriglyceridemia.
- To assess the impact of multidrug regimens on lipid parameters and patient health outcomes.
Main Methods:
- A study involving 40 patients at an academic lipid referral clinic.
- A mean follow-up period of 1.98 years with an average of 3.5 medications used per patient.
- Monitoring of lipid parameters, body mass index, and hemoglobin A1C levels.
Main Results:
- Significant reductions were observed in total cholesterol (45% mean reduction), triglyceride levels (50% median reduction), and non-high-density lipoprotein cholesterol (27% mean reduction).
- Mean body mass index decreased significantly, and hemoglobin A1C showed a trend towards reduction in diabetic patients.
- No serious adverse events such as rhabdomyolysis or significant elevations in liver function tests were reported.
Conclusions:
- Multidrug therapy (average 3.5 drugs) is an effective and well-tolerated treatment for severe hypertriglyceridemia.
- A two-year follow-up demonstrated the efficacy of combination therapy in managing high triglyceride levels.
- This approach offers a viable option for patients requiring more intensive lipid management.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:30Drug toxicity: Drug–Drug Interaction
Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...